Procter & Gamble Health Limited (PGHL.NS)
INR 5467.25
(0.04%)
INR 5467.25
(0.04%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 95.6 Million INR | -20.33% |
| 2022 | 120 Million INR | 324.03% |
| 2021 | 28.3 Million INR | -62.81% |
| 2020 | 76.1 Million INR | 0.0% |
| 2019 | - INR | -100.0% |
| 2018 | 65.3 Million INR | -2.68% |
| 2017 | 67.1 Million INR | 0.0% |
| 2016 | - INR | -100.0% |
| 2015 | 10.8 Million INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2013 | - INR | 0.0% |
| 2012 | - INR | 0.0% |
| 2011 | - INR | 0.0% |
| 2010 | - INR | 0.0% |
| 2009 | - INR | 0.0% |
| 2008 | - INR | 0.0% |
| 2007 | - INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 FY | 95.6 Million INR | -20.33% |
| 2023 Q4 | 95.6 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 108 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 120 Million INR | 324.03% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 120 Million INR | 0.0% |
| 2022 Q2 | 134.9 Million INR | 0.0% |
| 2021 Q4 | 28.3 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 2.9 Million INR | 0.0% |
| 2021 FY | 28.3 Million INR | -62.81% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q2 | 95.2 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 76.1 Million INR | 0.0% |
| 2020 FY | 76.1 Million INR | 0.0% |
| 2020 Q1 | - INR | 0.0% |
| 2019 Q4 | - INR | 0.0% |
| 2019 FY | - INR | -100.0% |
| 2019 Q1 | - INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2018 FY | 65.3 Million INR | -2.68% |
| 2018 Q2 | 65.3 Million INR | 0.0% |
| 2018 Q4 | - INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | 0.0% |
| 2017 FY | 67.1 Million INR | 0.0% |
| 2017 Q4 | - INR | 0.0% |
| 2017 Q2 | 67.1 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q3 | - INR | 0.0% |
| 2016 Q4 | - INR | 0.0% |
| 2016 FY | - INR | -100.0% |
| 2016 Q2 | - INR | 0.0% |
| 2015 FY | 10.8 Million INR | 0.0% |
| 2015 Q4 | - INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 27.6 Million INR | 0.0% |
| 2015 Q1 | - INR | 0.0% |
| 2014 Q3 | - INR | 0.0% |
| 2014 Q2 | - INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2014 FY | - INR | 0.0% |
| 2014 Q4 | - INR | 0.0% |
| 2013 Q3 | - INR | 0.0% |
| 2013 Q1 | - INR | 0.0% |
| 2013 FY | - INR | 0.0% |
| 2013 Q2 | - INR | 0.0% |
| 2013 Q4 | - INR | 0.0% |
| 2012 FY | - INR | 0.0% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2011 FY | - INR | 0.0% |
| 2011 Q2 | - INR | 0.0% |
| 2011 Q4 | - INR | 0.0% |
| 2010 FY | - INR | 0.0% |
| 2009 FY | - INR | 0.0% |
| 2008 FY | - INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | 93.317% |
| Ind-Swift Limited | 10.13 Billion INR | 99.057% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 97.128% |
| Sakar Healthcare Limited | 793.51 Million INR | 87.952% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 99.856% |
| Innova Captab Limited | 2.45 Billion INR | 96.1% |
| Divi's Laboratories Limited | 30 Million INR | -218.667% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -107.907% |
| Morepen Laboratories Limited | 289.99 Million INR | 67.034% |
| Mankind Pharma Limited | 2.07 Billion INR | 95.385% |
| Sequent Scientific Limited | 4.87 Billion INR | 98.04% |
| Wanbury Limited | 1.16 Billion INR | 91.793% |
| Laurus Labs Limited | 25.77 Billion INR | 99.629% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 98.496% |
| Glenmark Life Sciences Limited | 171.48 Million INR | 44.25% |
| Alembic Limited | 91.5 Million INR | -4.481% |
| Hikal Limited | 8.17 Billion INR | 98.831% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 98.137% |
| Neuland Laboratories Limited | 953.89 Million INR | 89.978% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 97.469% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 99.223% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | 70.818% |
| Themis Medicare Limited | 957.92 Million INR | 90.02% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 98.811% |
| Lupin Limited | 29.21 Billion INR | 99.673% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -453.145% |
| Wockhardt Limited | 23.56 Billion INR | 99.594% |
| Vaishali Pharma Limited | 134.91 Million INR | 29.142% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 96.649% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -6.923% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 99.739% |
| FDC Limited | 205.18 Million INR | 53.408% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 99.522% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | 69.791% |
| Eris Lifesciences Limited | 27.81 Billion INR | 99.656% |
| Venus Remedies Limited | 413.3 Million INR | 76.869% |
| ZIM Laboratories Limited | 1.08 Billion INR | 91.215% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 90.425% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -385.279% |
| Shilpa Medicare Limited | 9.37 Billion INR | 98.98% |
| Albert David Limited | 33.24 Million INR | -187.588% |
| Ajanta Pharma Limited | 352.8 Million INR | 72.902% |
| Hester Biosciences Limited | 2.44 Billion INR | 96.088% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | 85.291% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 99.055% |
| Gufic Biosciences Limited | 3.32 Billion INR | 97.128% |
| Windlas Biotech Limited | 36.41 Million INR | -162.565% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | 69.508% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 90.294% |
| Granules India Limited | 13.15 Billion INR | 99.273% |
| Aarti Drugs Limited | 5.64 Billion INR | 98.306% |
| Bal Pharma Limited | 1.39 Billion INR | 93.154% |
| Alkem Laboratories Limited | 14.18 Billion INR | 99.326% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 99.708% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -796.138% |
| Medicamen Biotech Limited | 308.17 Million INR | 68.978% |
| Unichem Laboratories Limited | 2.47 Billion INR | 96.138% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | 60.802% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -2078.173% |
| Valiant Laboratories Limited | 767.08 Million INR | 87.537% |
| Orchid Pharma Limited | 1.35 Billion INR | 92.928% |
| Medico Remedies Limited | 80.5 Million INR | -18.752% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | 42.484% |
| Ipca Laboratories Limited | 14.38 Billion INR | 99.335% |
| Brooks Laboratories Limited | 56.41 Million INR | -69.446% |
| Syncom Formulations (India) Limited | 724.86 Million INR | 86.811% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.982% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 99.762% |
| NATCO Pharma Limited | 3.71 Billion INR | 97.425% |
| Suven Life Sciences Limited | 7.09 Million INR | -1247.048% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 95.058% |
| Strides Pharma Science Limited | 25.16 Billion INR | 99.62% |
| Indoco Remedies Limited | 6.71 Billion INR | 98.577% |
| Alpa Laboratories Limited | 52.46 Million INR | -82.217% |
| Lasa Supergenerics Limited | 220.76 Million INR | 56.695% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | 84.366% |